RECITAL trial #CTD with #ILD RCT of #rituximab vs #cyclophosphamide showed value overall with each Rx. Only 6 months as then maybe you would retreat w rituximab? Not superior on lungs but in #scleroderma-skin improvement better w RTX. #ACRBest #ACR22 @RheumNow abst#3 Impt for Rx https://t.co/lX1YPsr5U6